ADARx Pharmaceuticals, Inc.
- Last sale
- Nov 12, 2026 · +12.49%
- Market cap
- $1.65B
- 111.19M shares
- Filings
- 51
Q3 2026
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026+373.9% FY25 yoy
- $1.65B
- —
- —
- 2.9×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
ADARx Pharmaceuticals, Inc. is the 108th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BKLRAKailera Therapeutics, Inc.———$1.7BSTOKStoke Therapeutics, Inc.$184.4M404.5%3.7%$1.7BPGENPrecigen, Inc.$9.7M146.7%2,588.2%$1.7B
ADRXADARx Pharmaceuticals, Inc. (this company)———$1.7B
SLSSELLAS Life Sciences Group, Inc.———$1.6BGENBGenerate Biomedicines, Inc.———$1.6BANIPANI Pharmaceuticals Inc$883.4M43.8%8.9%$1.6BNBTXNanobiotix S.A.———$1.6BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
ADARx Pharmaceuticals, Inc. · CIK 1802369 · Engraved from SEC EDGAR